Clinical Laserthermia Systems
Logotype for Clinical Laserthermia Systems

Clinical Laserthermia Systems (CLS) investor relations material

Clinical Laserthermia Systems Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Clinical Laserthermia Systems
Q3 2026 earnings summary13 Nov, 2026

Executive summary

  • Q3 revenue returned to YoY growth, up 80% to SEK 5.0m, with steady Prism deliveries supporting the partnership-led neurosurgery strategy.

  • The rights issue raised approximately SEK 31m before costs; full-year 2026 outlook remains double-digit revenue growth vs 2025, subject to financing and delivery timing.

Financial highlights

  • Q3 net sales were SEK 5.025m vs SEK 2.799m YoY; gross margin remained above 60%.

  • 9M net sales were SEK 13.952m vs SEK 16.657m, down 16% YoY; operating loss was SEK 30.300m vs SEK 18.194m.

  • Q3 operating loss was SEK 7.125m vs SEK 7.419m; net loss was SEK 5.415m vs SEK 8.137m. 9M net loss was SEK 24.871m vs SEK 29.715m.

  • Q3 EPS was SEK -0.15 vs -0.32; 9M EPS was SEK -0.75 vs -1.23.

Outlook and guidance

  • Full-year 2026 revenue is expected to grow by double digits vs 2025; quarterly results may vary with deliveries, system placements, site activation and procedure volumes.

  • Outlook assumes planned financing activities are completed to support the commercialization strategy and known financial commitments.

  • Near-term priorities are U.S. commercial execution and regulatory work for European market access; revenue growth depends on new placements and utilization of installed systems.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Clinical Laserthermia Systems earnings date

Logotype for Clinical Laserthermia Systems
Q4 202619 Feb, 2027
Clinical Laserthermia Systems
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Clinical Laserthermia Systems earnings date

Logotype for Clinical Laserthermia Systems
Q4 202619 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Clinical Laserthermia Systems AB is a Swedish medical technology company focused on developing minimally invasive laser-based treatment systems for cancer and neurosurgery. The company’s flagship product is the TRANBERG Thermal Therapy System, which is designed for precision laser ablation of solid tumors. This system enables high-precision, image-guided treatments for conditions such as prostate cancer and brain lesions. CLS is also advancing imILT (immunostimulating interstitial laser thermotherapy), which combines laser ablation with immune system stimulation to treat various types of tumors, including those in the liver, lungs, and pancreas. The company is headquartered in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.